Please assess the completion status of the following clinical trial:

Trial Title: A Study of CP-751,871 in Patients With Recurrent Squamous Head and Neck Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Recurrent and/or metastatic head and neck squamous cell carcinoma not amenable to curative treatment with surgery and/or chemotherapy and/or radiation.~2. Recurrence must be confirmed by anatomopathology (cytology or biopsy)~3. At least one measurable lesion by MRI or CT-scan.~4. Failed or relapsing after first line chemotherapy including a platinum\* or a taxane-based chemotherapy regimen~5. Patients ineligible for chemotherapy could be included in first line~6. ECOG performance status 0 -2, in stable medical condition~7. Patients must have an expected survival of at least 3 months.~8. Paraffin-embedded tumor tissue available for immunohistochemistry~9. Patients must be over 18 years old and must be able to give written informed consent~10. Women of child-bearing age or sexually active female patients with reproductive potential must have a negative pregnancy test (serum or urine within the 7 days prior to enrollment).~11. Patients must have adequate organ function (Hemoglobin ≥ 8 g/100 ml, Neutrophils ≥ 1,000/mm3, Platelets ≥ 75,000/mm3, total bilirubin \<1.5 times the upper limit of normal (ULN) for age (except for Gilbert's syndrome patients), serum alanine aminotransferase (ALT) \<2.5 ´ ULN for age, aspartate aminotransferase (AST) \<2.5 ´ ULN for age , serum creatinine £1.5 x ULN for age~12. Acceptance of giving 20 ml of blood for eventual research at baseline~13. Acceptance of giving two plasma samples (3ml) at baseline and after 3 weeks of treatment~14. Signed informed consent prior to beginning protocol specific procedure~15. Sexually active patients must use effective contraception during the period of therapy and up to 150 days after the last dose of CP-751,871. Acceptable contraception includes, but is not limited to: oral hormone therapy, partner vasectomy, or double barrier contraception (which is defined as a male condom plus spermicide in combination with either a female condom, or diaphragm, or cervical cap or intrauterine device).~Exclusion Criteria:~1. Non-squamous head and neck cancer~2. Nasopharynx cancer~3. Brain metastases~4. More than two lines of chemotherapy for palliative treatment (except if chemotherapy was given as a part of a multimodal treatment given with a curative intent)~5. Surgery or irradiation or investigational drugs within 4 weeks before study inclusion~6. Significant active cardiac disease including: uncontrolled high blood pressure, unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, or serious cardiac arrhythmias~7. Subjects who are receiving chronic high dose immunosuppressive steroid therapy within 2 weeks prior to enrollment (³100 mg prednisone per day or \>40 mg dexamethasone per day).~8. Other uncontrolled illnesses (active infections requiring antibiotics, bleeding disorders, uncontrolled diabetes ...)~9. Previous malignancy, with exception of a history of a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix~10. Other concomitant anticancer therapies.~11. Previous treatment with anti-EGFR therapy is not an exclusion criteria.~12. Prior anti-IGF-1R therapy~13. Organic brain syndrome or significant psychiatric abnormality that would preclude participation in the full protocol and follow up.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): CP-751,871 will be administered as an open-label intravenous solution. Patients will remain under clinical observation for one hour post-infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).